![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -3.28% | 14.75 | 14.50 | 15.00 | 15.25 | 14.50 | 15.25 | 68,434 | 14:37:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.19 | 13.91M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/5/2017 07:56 | I like the sentence " We believe working with Nutrilinea, and similar partners around the world, provide the best opportunity of building LPLDL® into a global brand. " For me the SIMILAR PARTNERS is excellent news IMHO | ![]() joyjoy13 | |
09/5/2017 07:55 | Have to say I don't think you will see a huge jump today - hope I'm wrong though! | ![]() whl2 | |
09/5/2017 07:54 | Some people get OPTI's strategy. Others obviously don't. | ![]() parob | |
09/5/2017 07:54 | Sounds like a few may be short here...and sounding a bit desperate! IMO | ![]() f3rdinand | |
09/5/2017 07:54 | I would not expect a non-exclusive agreement to include a minimum commitment. Best wishes - Mike | ![]() spike_1 | |
09/5/2017 07:53 | Great RNS this morning. No I'm just joking. This is the key line:- "it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe" So what? Will they sell any? What will Opti get? "Nutrilinea intends to produce, promote, market and commercialise OptiBiotix's CholBiome™ and CardioBiome™ products to their European network with the aim of maximising the financial return for both parties." If Nutrilinea are producing, promoting, marketing and commercialising then Opti's share of any sales will be virtually "s*d all" anyway. Nutrilinea are hardly an industry giant either. Revenues and profits are still years away. Don't stop dreaming though. Ramptastic stuff. Aimho of course. | ![]() michaelmouse | |
09/5/2017 07:53 | that was the word i was looking for , underwhelming We expected a ferrari and they brung us a reliant robin with Trotters Independent trading on the side | ![]() nobilis | |
09/5/2017 07:52 | QS, people who keep spouting on about revenues need to think outside the box a little, those of us who are willing to join the dots can already see how large revenues will become in the near(ish) future. The BB and SoH have given countless examples of competitors in the same field, their revenue profile and Mcap. It doesn't take a great leap of imagination to see OPTI has all the tools to become a significant player in this market. I'm afraid those waiting for the $$ revenues will most likely miss the next big step up, missing out to those who have the foresight and risk appetite to lead the way. | ![]() trotterstrading | |
09/5/2017 07:51 | Very underwhelming. | ![]() monkeywench1 | |
09/5/2017 07:51 | LPLDL® Non-Exclusive European License Agreement : 09 May 2017 : RNS & Investor News | Better Science, better Health | OptiBiotix Health Plc hxxp://www.optibioti | ![]() joyjoy13 | |
09/5/2017 07:51 | Deals will snowball as we now have Sacco, Nutrilinea, SOH, Luis and Per all promoting our cardio products! | ![]() parob | |
09/5/2017 07:50 | did you want exclusive then?!! | ![]() nicktopten | |
09/5/2017 07:48 | Non exclusive and with no minimum committment Rubbish! | ![]() nobilis | |
09/5/2017 07:42 | THEN we can start seeing what the actual revenues generated are over the next year..... | ![]() qs99 | |
09/5/2017 07:41 | Still got the big US partner announcement to come to. Still a lot more to come and all top drawer partners. | ![]() shrewdmole | |
09/5/2017 07:39 | Deals will snowball now, real tangible progress is being made.. yet it's just the start, so much news flow to come as deals, partnerships, products, and revenues are announced. OPTI will be a life changer, not just for shareholders, but people all over the world | ![]() trotterstrading | |
09/5/2017 07:20 | Great news! So we now have 4 revenue streams confirmed:- GoFigure- Sacco- HLH BioPharma Vertriebs GmbH - NutriliniaThe last 3 were announced in the last 2 months alone. IMO we'll see the frequency of deal announcements speed up as the snowball effect takes hold. I wonder how many revenue streams we'll have confirmed by the end of the year.Surely we'll now be getting the attention of some new institutions. | ![]() parob | |
09/5/2017 07:08 | Also like how SOH states he 'chose' Nutrinea! Being able to pick and choose speaks volumes for our product!! | ![]() f3rdinand | |
09/5/2017 07:07 | Well done all who spotted the nutrilinea connection! Another large piece of the jigsaw announced today! | ![]() f3rdinand | |
09/5/2017 07:06 | OptiBiotix Health plc ("OptiBiotix" or the "Company") LPLDL® Non-Exclusive European License Agreement OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe with a view to maximising the financial return for both parties. Nutrilinea has over 15 years' experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea provides products to both national and international businesses in Europe and the USA, and is one of Europe's fastest growing providers of food supplements, doubling revenues in the last 12 months to over €30m per annum. Nutrilinea is based in Italy and has established an international reputation for providing innovative product formulations and presentations for different markets, including products containing some of the world's best selling probiotic strains. Nutrilinea intends to produce proprietary formulations containing OptiBiotix's LPLDL® strain developed to reduce cholesterol levels and blood pressure (CholBiome™), and cardiovascular risk (CardioBiome™) This pre-launch agreement is another step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's expertise and market reach to serve multiple consumer healthcare and pharmaceutical markets around the world. Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain for the reduction of cholesterol and cardiovascular risk. We chose Nutrilinea due to its industry reputation, extensive European network, and record of doubling revenues in the last 12 months. We believe working with Nutrilinea, and similar partners around the world, provide the best opportunity of building LPLDL® into a global brand. We see this as another step in building revenues and market presence of LPLDL® as the 'Intel' inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world." | ![]() someuwin | |
08/5/2017 22:31 | Hi MAR the ParaSAR hasnt reversed direction yet(well according to my charts Sharescope and Pro realtime) Linear chart | ![]() john henry | |
08/5/2017 19:57 | ParaSAR (Parabolic Stop And Reverse - the tiny dots) has Stopped And Reversed - it's an always-in-the-market trading signal that works well in trending stocks. That said, we have yet to prove we are trending again, but it's a start. According to my data we failed to stay above the 8 day ESA (yellow line) - pity. There's a lot to do to get back on a bull run, not least with all the noise overhead, but the indicators are turning up from oversold and a MACD crossover is now the one to look for. M Log scale daily candlestick chart: | ![]() marnewton |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions